Form 4: DENTSPLY SIRONA CEO Granted 1.1M Stock Options

DENTSPLY SIRONA Inc.'s President and CEO, Daniel T. Scavilla, was granted 1,102,600 stock options with an exercise price of $12.96, vesting over three years.

Summary

• Daniel T. Scavilla, President, CEO, and Board Member of DENTSPLY SIRONA Inc. (XRAY), was granted 1,102,600 stock options on August 8, 2025.
• The stock options have an exercise price of $12.96 per share.
• These options will vest in annual one-third increments over a three-year period, concluding on August 8, 2028.
• The options become exercisable starting August 8, 2026, and expire on August 8, 2035.
• Scavilla also reported a disposition of 17,475.049 shares of common stock.

Sentiment

Score: 7

Explanation: The grant of stock options to the CEO is a positive signal of long-term incentive alignment, though the disposition of shares, while likely for tax purposes, is a minor neutral point. Overall, it's a standard and generally positive compensation event.

Positives

• The grant of 1,102,600 stock options aligns management's incentives with shareholder value creation.
• The options have a 10-year expiration period, providing a long-term incentive for the CEO.

Negatives

• The disposition of 17,475.049 shares of common stock by the CEO, though likely for tax purposes, reduces direct share ownership.

Risks

• Potential future dilution for existing shareholders if the granted stock options are exercised, increasing the total number of outstanding shares.
• The value of the stock options is dependent on the future performance of DENTSPLY SIRONA Inc.'s stock price exceeding the exercise price of $12.96.

Future Outlook

NA

Industry Context

This filing reflects a standard executive compensation practice within publicly traded companies, particularly in the healthcare or medical device sector where long-term incentives like stock options are common to align leadership with company performance.

Comparison to Industry Standards

• The grant of stock options to a CEO is a common practice across industries, including the dental and medical device sectors, aligning executive incentives with long-term shareholder value.
• The vesting schedule of one-third increments over three years is a typical structure for executive equity awards, similar to those seen at companies like Align Technology (ALGN) or Henry Schein (HSIC) for their senior executives.
• The 10-year expiration period for the options is standard for such grants, providing ample time for the executive to realize value.

Stakeholder Impact

• Shareholders: Potential for long-term value creation if the CEO's incentives align with stock price appreciation; potential minor dilution if options are exercised.
• Employees: May signal stability and confidence in leadership.

Next Steps

• Continued vesting of the granted stock options over the next three years until August 8, 2028.
• Potential exercise of stock options by Daniel T. Scavilla after they become exercisable starting August 8, 2026.

Key Dates

Recommendation

This Form 4 filing primarily details a routine executive compensation event (stock option grant) and a likely tax-related share disposition. It does not provide new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. The option grant aligns management incentives, which is generally positive, but it's a standard practice and not a catalyst for a strong buy or sell decision. Therefore, a "hold" recommendation is appropriate as it maintains the current position based on existing company fundamentals.

Keywords

DENTSPLY SIRONA, XRAY, Stock Options, CEO Compensation, Insider Trading, Executive Compensation, Form 4, Daniel T. Scavilla, Equity Grant, Dental Industry